Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

Inclusion Criteria:

* Relapsed or refractory follicular lymphoma grade I-II
* Tumor verified to be CD20 positive
* CT scan showing demarcated lesions

Exclusion Criteria:

* Previous treatment with rituximab resulting in less than partial response
* Previous radioimmunotherapy
* Previous stem cell transplantation
* Received the following treatments within 4 weeks prior to entering this study:

  1. Anti-cancer therapy
  2. Glucocorticosteroids unless less than 10 mg prednisolone/day
  3. Radiotherapy
* Received Mitomycin C or Nitrosoureas within 6 weeks prior to entering this trial
* HIV positivity
* Hepatitis B or hepatitis C
* Uncontrolled or chronic bacterial, fungal or viral infection
* Other cancer diseases, except certain skin cancers, cervix cancer and breast cancer
* Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, lung, heart, hormonal, nerve or blood diseases
* WHO performance status of 3 or 4
* If you are participating in another trial with a different new drug 4 weeks before you enter this trial
* Current participation in any other clinical study
* Pregnant or breast-feeding women
* Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial